• How do you define “first in class”?

    A first‑in‑class therapy refers to an anticancer drug with an entirely novel mechanism of action.

  • Why do you focus on small molecule drugs?

    We believe small molecules offer the most advantageous modality for oral administration and carry a lower manufacturing risk due to their well‑established production processes.

  • Which pipeline are you mainly focusing on?

    For the foreseeable future, our primary focus will be on CTX‑712, our lead pipeline candidate and a CLK inhibitor.

  • What differentiates your company from competitors?

    Our team consists of seasoned drug‑discovery professionals with decades of experience.
    We were among the earliest to recognize the importance of RNA regulation stress as a new cancer hallmark and have advanced our research ahead of competitors.
    We consider this scientific leadership and development speed to be a core competitive strength.